On February 22, 2022 Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, reported that TYRA management will be participating in a corporate panel discussion at the Cowen 42nd Annual Healthcare Conference, taking place virtually March 7-9, 2022 (Press release, Tyra Biosciences, FEB 22, 2022, View Source [SID1234608837]). Details are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Corporate Panel Details:

Targeted Oncology – Todd Harris, CEO of TYRA
Tuesday, March 8, 2022, 9:10 am ET
A live webcast of the panel will be available on the Company’s website at View Source in the "For Investors" section.